Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074303 · ClinicalTrials.gov registry record · Phase 2
Beta-glucan and Immune Response to Influenza Vaccine
A Phase 2 study of Healthy Aging, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT05074303: Completed Phase 2 study of Healthy Aging, sponsored by University of Florida.
NCT05074303 is a Phase 2 study of Healthy Aging that has completed, run by University of Florida. The registered enrollment target is 78 participants, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074303, a Phase 2 study of Healthy Aging, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
Primary Outcome
Change in influenza-specific antibody influenza A titer to the influenza vaccine after beta-glucan supplementation. Titer from 0 to 1024; higher titer indicates stronger immune response.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Beta-glucan
- BIOLOGICAL Influenza Vaccine
Study Locations (1)
Florida
- Food Science and Human Nutrition Department, University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2022-07-18 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 2 |
What the finished NCT05074303 record still lists
NCT05074303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 119-participant average among 40 other Healthy Aging trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05074303 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05074303 about?
NCT05074303 is a clinical study titled "Beta-glucan and Immune Response to Influenza Vaccine". This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
What is the current status of trial NCT05074303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2022-07-18. Estimated completion is 2024-08-28.
What conditions does trial NCT05074303 study?
This clinical trial studies the following conditions: Healthy Aging.
What interventions are being tested in trial NCT05074303?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Beta-glucan (DIETARY_SUPPLEMENT), Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05074303?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05074303 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05074303's enrollment target sits among peer trials
78 20th of 40 higher than 21 of 40 other Healthy Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
RECRUITING · Phase 2
-
A Novel Computer-Based Functional Skills Assessment and Training Program
ACTIVE NOT RECRUITING · Phase 2
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
RECRUITING · NA
-
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI